155 related articles for article (PubMed ID: 33023774)
1. Parent, provider and vaccinee preferences for HPV vaccination: A systematic review of discrete choice experiments.
Lack A; Hiligsmann M; Bloem P; Tünneßen M; Hutubessy R
Vaccine; 2020 Oct; 38(46):7226-7238. PubMed ID: 33023774
[TBL] [Abstract][Full Text] [Related]
2. Parental preferences for HPV vaccination in junior middle school girls in China: A discrete choice experiment.
Zhu S; Chang J; Hayat K; Li P; Ji W; Fang Y
Vaccine; 2020 Dec; 38(52):8310-8317. PubMed ID: 33223307
[TBL] [Abstract][Full Text] [Related]
3. Vaccine preferences driving vaccine-decision making of different target groups: a systematic review of choice-based experiments.
Diks ME; Hiligsmann M; van der Putten IM
BMC Infect Dis; 2021 Aug; 21(1):879. PubMed ID: 34454441
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the barriers to implementing human papillomavirus vaccination programs in low- and middle-income countries in the Asia-Pacific.
Ver AT; Notarte KI; Velasco JV; Buac KM; Nazareno J; Lozañes JA; Antonio D; Bacorro W
Asia Pac J Clin Oncol; 2021 Dec; 17(6):530-545. PubMed ID: 33636046
[TBL] [Abstract][Full Text] [Related]
5. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
6. "HPV? Never heard of it!": a systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination.
Hendry M; Lewis R; Clements A; Damery S; Wilkinson C
Vaccine; 2013 Oct; 31(45):5152-67. PubMed ID: 24029117
[TBL] [Abstract][Full Text] [Related]
7. Risk as an attribute in discrete choice experiments: a systematic review of the literature.
Harrison M; Rigby D; Vass C; Flynn T; Louviere J; Payne K
Patient; 2014; 7(2):151-70. PubMed ID: 24566923
[TBL] [Abstract][Full Text] [Related]
8. Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review.
Ekwunife OI; Grote AG; Mosch C; O'Mahony JF; Lhachimi SK
Syst Rev; 2015 May; 4():68. PubMed ID: 25963745
[TBL] [Abstract][Full Text] [Related]
9. Patients' preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments.
Tünneßen M; Hiligsmann M; Stock S; Vennedey V
J Med Econ; 2020 Jun; 23(6):546-556. PubMed ID: 32011209
[No Abstract] [Full Text] [Related]
10. Patients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments.
Bien DR; Danner M; Vennedey V; Civello D; Evers SM; Hiligsmann M
Patient; 2017 Oct; 10(5):553-565. PubMed ID: 28364387
[TBL] [Abstract][Full Text] [Related]
11. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments.
Harrison M; Milbers K; Hudson M; Bansback N
BMJ Open; 2017 May; 7(5):e014719. PubMed ID: 28515194
[TBL] [Abstract][Full Text] [Related]
12. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
13. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review.
Mezei AK; Armstrong HL; Pedersen HN; Campos NG; Mitchell SM; Sekikubo M; Byamugisha JK; Kim JJ; Bryan S; Ogilvie GS
Int J Cancer; 2017 Aug; 141(3):437-446. PubMed ID: 28297074
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
Ekwunife OI; Lhachimi SK
BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study.
Perez S; Tatar O; Shapiro GK; Dubé E; Ogilvie G; Guichon J; Gilca V; Rosberger Z
BMC Public Health; 2016 Dec; 16(1):1223. PubMed ID: 27919239
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.
Baji P; García-Goñi M; Gulácsi L; Mentzakis E; Paolucci F
Eur J Health Econ; 2016 Sep; 17(7):791-9. PubMed ID: 26296623
[TBL] [Abstract][Full Text] [Related]
18. "It All Depends": A Qualitative Study of Parents' Views of Human Papillomavirus Vaccine for their Adolescents at Ages 11-12 years.
Hansen CE; Credle M; Shapiro ED; Niccolai LM
J Cancer Educ; 2016 Mar; 31(1):147-52. PubMed ID: 25600376
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents.
La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK
BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
